Studies have indicated that in patients undergoing ICI (immune checkpoint inhibitor) therapy for malignant melanoma, a lower baseline level of IL-6 is strongly linked to the development of immune-related adverse events such as colitis [61,62]. The gene discussed is IL6; the disease is melanoma.